Seropositive Reaction Rates of 9 B-Cell Epitopes of the SARS-CoV-2 Spike Protein and the Relationship between the Epitopes and Neutralizing Antibody

Li Zhu\textsuperscript{a,b}, Yunwen Zhang\textsuperscript{c}, Zhengrong Yang\textsuperscript{b}, Baisheng Li\textsuperscript{d}, Tiejian Feng\textsuperscript{b}, Xuan Zou\textsuperscript{b}, Jianfan He\textsuperscript{b}, Taiping He\textsuperscript{e}, Junling Li\textsuperscript{e}, Ning Liu\textsuperscript{b}, Wei Li\textsuperscript{a}, Xiaohui Wang\textsuperscript{b}

\textsuperscript{a}School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China; \textsuperscript{b}Shenzhen Center for Disease Control and Prevention, Shenzhen, China; \textsuperscript{c}West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China; \textsuperscript{d}Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China; \textsuperscript{e}School of Public Health, Guangdong Medical University, Zhanjiang, China

Keywords
Severe acute respiratory syndrome coronavirus 2 · Spike protein · Epitopes · Neutralizing antibody

Abstract

\textbf{Objective:} The aim of the study was to analyze the relationship between serum antibody and neutralizing antibody titers in convalescent coronavirus disease 2019 (COVID-19) patients with different disease severities, and the seropositive reaction rates of 9 reported B-cell epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

\textbf{Methods:} Serum IgG and total antibody titers of 165 convalescent COVID-19 patients were determined by chemiluminescence, the serum neutralization antibody titers were determined by microneutralization assay, and the S/CO values of 9 peptides were detected by indirect enzyme-linked immunosorbent assay. Correlations between the aforementioned indexes were statistically analyzed, and differences in patients with different disease severities were evaluated.

\textbf{Results:} IgG, total antibody, and neutralizing antibody titers increased with disease severity. The positive rate of the receptor-binding region (RBD) was 100%, and the average positive rate for all the 9 peptides was above 50% in 165 patients. IDf showed the highest rate of positivity (86.06%), with a rate of 95% for the (IDf + IDa) pattern. Moreover, S/CO values of RBD and mix (IDh) were significantly correlated with IgG, total antibody titers, and neutralizing antibody titers (\(p < 0.001\)), whereas the S/CO values for other 8 peptides showed no obvious correlation.

\textbf{Conclusion:} In this study, a large sample was used to confirm that the peptide IDf had a high positive reaction rate for all patients (86.06%) and also had the highest detection rate in asymptomatic patients (86.67%). Only long peptide and mixed peptide showed correlation with neutralizing antibody titers, suggesting that the ability of SARS-CoV-2 antibody to neutralize virus infectivity may require the interaction of multiple sites.
Introduction

The epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed a serious threat to the global public health [1, 2]. Scientists have carried out valuable research on this topic, and the study of B-cell epitopes is of great significance for the development of vaccines and antibody detection reagents. The spike (S) protein of SARS-CoV-2 plays an important role in the process of virus binding to the angiotensin-converting enzyme 2 receptor and cell membrane fusion as well as entry into host cells. Thus, blocking the binding of S protein and angiotensin-converting enzyme 2 receptor is an effective strategy to prevent coronavirus entering target cells [3–5]. On July 1, 2020, Zhang et al. [6] identified 9 linear immunodominant (ID) epitopes by using the serum samples from 39 patients with coronavirus disease 2019 (COVID-19) and found that 4 linear immune loci were located in the receptor-binding region (RBD). In the present study, we used serum samples from 165 COVID-19 patients to confirm the positive reaction rates of 9 epitopes and analyzed the relationship between the S/CO values of 9 epitopes, the IgG concentration, and neutralizing antibody titers.

Materials and Methods

Serum Source of Discharged Patients

Blood samples and clinical information of 165 discharged COVID-19 patients were collected during March 5, 2020 to May 12, 2020, in Shenzhen, China. These discharged patients were treated at the Third People’s Hospital of Shenzhen and met the COVID-19 discharge criteria. According to the classification of clinical symptoms in the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition) promulgated by the National Health Commission of the People’s Republic of China [7], 165 COVID-19 patients were divided into asymptomatic patients (30, 18.18%), mild patients (22, 13.33%), moderate patients (106, 64.24%), and severe and critically ill patients (7, 4.24%) (there was one critical case included to facilitate the statistics). The median age of all patients was 33 years, and the proportion of female patients was 52.72%. At the same time, serum samples from 20 healthy people were collected as the negative control group. The control population was free of SARS-CoV-2 infection, and HIV, hepatitis C, and syphilis serum tests were all negative. To ensure biosafety, the serum samples were incubated at 56°C for 30 min to avoid potential risks. This study was reviewed by the Ethics Committee of Shenzhen for Disease Control and Prevention in Guangdong Province (QS2020070048).

Total Antibody and IgG Antibody Detection

The Caris200 Automatic Chemiluminescence Instrument and Chemiluminescence Kit (Xiamen Wantai Biological Pharmacy Enterprise Co., Ltd. Xiamen, China) were used to detect IgG and total antibody levels. Both the instrument and reagent were certified by the China National Medical Products Administration (NMPA) (National Instrument Registration Certificate 20203400198). This method used the SARS-CoV-2 S-RBD as the detection antigen, and the detection indicator was COI value. The COI was the sample detection value/cutoff value, and the cutoff value was the average serum test result from 5 healthy people. The serum samples with COI above 1 were considered positive.

Microneutralization Assay

Neutralizing antibody titers were measured by microneutralization assay. The SARS-CoV-2 virus isolate (20SF014/Vero-E6/3) and the Vero-E6 cell line were used for this assay. Vero-E6 cells were seeded in 96-well plates at 1 × 10⁴ cells/100 μL and cultured for 12 h (37°C, 5% CO₂). After heat inactivation at 56°C for 30 min, the serum was diluted by gradient dilution of 1:4, 1:16, 1:64, 1:256, and 1:1,024. The SARS-CoV-2 virus was incubated with serum at a titer of 104.67 TCID₅₀/50 μL for 2 h. Next, 100 μL of diluted serum and virus sample mixture were added to wells containing the Vero-E6 cells. Viral positive controls were prepared with the titers of 100 TCID₅₀/50 μL, 10 TCID₅₀/50 μL, 1 TCID₅₀/50 μL, and 0.1 TCID₅₀/50 μL, respectively, and cultured with the samples simultaneously. When complete cytopathic effect occurred in the positive control wells of TCID₅₀/50 μL virus, the level of cytotoxic effect was recorded. For each serum sample, the reciprocal of the highest dilution of serum that could protect 50% of the cell well from cytopathic effect was defined as the SARS-CoV-2 neutralizing antibody titer of that sample. The titer was above 1:4, which was considered positive. All operations are performed in a level 3 biosafety laboratory.

Peptide Synthesis and Dissolution

The peptides used in this study were synthesized by Sangon Biotech Co., Ltd. (Shanghai) and transported in the form of freeze-dried powder. The quality of all peptides was detected by mass spectrometry, and the purity was 98%. Each peptide segment was 20–25 amino acid residues in length, with 5 overlapping amino acid residues in adjacent sequences. The solvent used for the dissolution of the peptide was prepared according to the instruction manual, that is, and dissolved in ultra-pure water or 75% ethanol, 25% ddH₂O (double-distilled water) and 5% formic acid.

Indirect Enzyme-Linked Immunosorbent Assay

The peptide solution with final concentration of peptides (2.5 μg/mL) was prepared (except peptide IDe: 0.5 μg/mL) by dissolving in carbonate buffer. The S-RBD (CUSABIO; # CSB-MP-3324GMY1b1) was used as the positive antigen control, with a final concentration of 0.2 μg/mL. Each well of a 96-well plate (# 42592; Corning) was added with 100 μL of peptide solution and coated overnight at 4°C. The plate was washed 5 times with 300 μL wash solution (0.05% Tween-20 and 1% bovine serum albumin in PBS). Blocking with 300 μL blocking solution (5% skim milk powder and 0.1% Tween-20 in PBS) for overnight at 4°C. The plate was washed 5 times and added 100 μL/well of inactivated serum from patients diluted at 1:80 in blocking buffer, followed by incubation at 37°C for 1 h after shaking. Each sample was test duplicate. The plate was washed and added 100 μL/well of solution containing rabbit anti-human IgG HRP conjugate (# 6759, diluted at 1:130,000; Abcam), followed by incubation at 37°C for 1 h. The plate was washed and added 100 μL/well of TMB (# EK0011; Multi
Science). After shaking, plates were incubated at room temperature in the dark for 25 min and added 100 μL/well of stop solution. The OD value was determined at 450 nm as the maximum absorption wavelength and 630 nm as the reference wavelength. Samples from a healthy person were used as negative controls, and 6 negative control wells were set for each plate. The cutoff value was based on the mean value of negative controls plus 3 times the standard deviation. The serum samples with an S/CO above 1 were considered positive.

**Data Analysis**

SPSS Statistics 21, GraphPad Prism 8.0, and Origin 2021 were used for statistical analysis and plotting. The χ² test was used to analyze the difference in the positive rate of different epitopes. The Kruskal-Wallis H test was used to analyze the difference in antibody titers (COI) and epitope S/CO values. Correlation analysis was carried out by using Spearman’s rank correlation, and the 3D structure of protein was analyzed online using by NCBI website. When \( p < 0.05 \), the difference was considered statistically significant: \(* p < 0.05\), \(** p < 0.01\), and \(*** p < 0.001\).

**Fig. 1.** Distribution of serum antibody levels in 165 convalescent COVID-19 patients with different disease severity. Total antibody levels (COI) (a), IgG levels (COI) (b), and neutralizing antibody titers (c). COI: sample detection value/cutoff value. Each small triangle represented the detection value of 1 sample. Data are shown as median (IQR). IQR, interquartile range; COVID-19, coronavirus disease 2019.
Fig. 2. S/CO values of each peptide and the positive reaction rates of the peptides in convalescent serum from COVID-19 patients by using indirect ELISA. a The S/CO values of each peptide in 165 convalescent COVID-19 serum samples. Each point represented per patient, and the data are represented as the median (interquartile range). b The overall seropositive reaction rates of the 8 short peptides in 165 convalescent COVID-19 serum samples. c-f The seropositive reaction rates of 8 short peptides in 165 convalescence COVID-19 patients with different disease severity. S/CO value: sample OD value/cutoff value, the sample with S/CO > 1 was regarded as positive, and the cutoff value was the average OD value of healthy people plus 3 times the SD. COVID-19, coronavirus disease 2019; ELISA, enzyme-linked immunosorbent assay.
Results

Description of the Antibody Levels of the Samples

This study measured total antibody, IgG antibody, and neutralizing antibody titers in 165 convalescent COVID-19 patients. The positive rates of total antibody and IgG were 98.78% (163/165). The median COI (interquartile range [IQR]) of total antibody and IgG were 128.39 (267.52) and 20.43 (8.39), respectively. The neutralizing antibody detection rate was 90.67% (136/150), and the median (IQR) was 1:32 (1:24). Overall, IgG, total antibody, and neutralizing antibody titers increased with disease severity (shown in Fig. 1a–c).

Positive Rates of the Reactions between Peptides and Serum

According to enzyme-linked immunosorbent assay results, the median S/CO (OD value/cutoff value) of the reactions between peptides (IDa to IDi) and serum ranged from 1.07 to 1.68 peptide mixture (mix [IDh]) among the 165 convalescent patients. The S/CO value of mix (IDh) was higher than that of other peptides (p < 0.001) (shown in Fig. 2a). Mix (IDh) is a mixed long peptide fragment with amino acid sites ranging from 522 to 646, including 125 amino acids. In terms of detection rate, we were unable to compare it with other short peptides.

As shown in figure, the overall positive reaction rates of 8 short peptides were as follows: (1) RBD was used as the positive control the positivity rate was revealed as 100% when reacting with all the serum samples from patients, with a median S/CO (IQR) of 18.46 (10.87). (2) For the short peptides, the overall positive reaction rates were 67.27% for IDa, 70.91% for IDb, 60% for IDc, 66.06% for IDd, 66.06% for IDe, 86.06% for IDf, 78.79% for IDg, and 78.79% for IDi. The positive rates of all peptides were >50% (shown in Fig. 2b). (3) Among these 8 peptides, the positive rate of IDf was significantly higher than that of the other peptides (p < 0.001). Regarding samples of different clinical types, IDf also showed an advantage in detection, especially in asymptomatic and mild patients, reaching a rate of >95% (shown in Fig. 2c–f). (4) Analysis of different peptide combinations showed that the overall positive rate was 94.55% for (IDb + IDf), and the positive rate of (IDb + IDf + IDg) was 97.57% (shown in Fig. 3a), both of which were significantly higher than the detection rate of IDf (p < 0.001). In addition, the combination of IDf with any peptide showed a positive reaction rate >90% (shown in Fig. 3b).
Fig. 4. Location of each peptide in the S protein genome and S protein 3D structure. And correlation analysis between peptide S/CO values with antibody levels. **a** Representative structures of some functional domains of the SARS-CoV-2 S protein. RBD, receptor-binding domain; FP, fusion peptide; HR1, heptad repeat region 1; HR2, heptad repeat region 2. **b** Spatial locations of the mix (IDh), IDf, and RBD peptides on the 3D structure of the SARS-CoV-2 S protein. The 3D structure of the SARS-CoV-2 S protein was obtained from the NCBI website (PDB ID: 6VXX). The 3 peptides are represented by 3 different colors: red denotes the RBD, yellow denotes mix (IDh), and green denotes IDf. **c** Correlation relationship between S/CO values of peptides with antibody titer. The number in the figure was the Spearman correlation coefficient, and the darker the color meant the stronger the correlation. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RBD, receptor-binding region.
Correlation Analysis between Peptides and Antibody Levels

The S protein of SARS-CoV-2 had 2 subunits: S1 and S2 [8–10]. Among the 9 peptides used in this study, IDi was located on the S2 subunit, whereas the others are located on S1 and 4 peptides, IDd, IDE, IDf, and IDg, are located in the RBD (shown in Fig. 4a). From the perspective of spatial location, mix (IDh) was close proximity to the RBD, and IDf is located in the RBD (shown in Fig. 4b).

The analysis showed that the S/CO values of RBD showed the highest correlation with IgG levels ($r = 0.73$, $p < 0.001$). Conversely, the S/CO values of all short peptides exhibited no correlation with IgG levels or total antibody levels. In the analysis of the correlations between the neutralizing antibody titers and peptides, the correlation coefficients between the neutralizing antibody titers and S/CO values of the RBD and mix (IDh) were 0.53 and 0.48, respectively ($p < 0.001$). In addition, correlation coefficients of mix (IDh) with total antibody levels, IgG levels, and RBD levels were 0.47, 0.42, and 0.39, respectively ($p < 0.001$) (shown in Fig. 4c), while there was no correlation between neutralizing antibody titers and the other peptides, including the 4 located in the RBD (shown in Fig. 4c).

Discussion

In July 2020, Zhang et al. [6] reported 9 B-cell linear epitopes of the SARS-CoV-2 S antigen. S antigen is the main antigen for virus neutralizing antibodies. Nowadays, research on its antigenic epitopes has important significance for vaccine development and diagnosis. At the beginning of this study, few S antigen epitopes have been reported, and the sample sizes of those studies were relatively small. The 9 peptides used in this study are the latest B-cell linear epitopes published by Zhang et al. [6].

Zhang et al. [6] reported the positive reaction rates of the 9 peptides to 35 serum samples were above 50%. In the present study, the 9 peptides were individually validated via serum samples from 165 convalescent COVID-19 patients. The results showed positive reaction rates of 9 peptides ranging from 60% to 86.06%, with the rate of short peptides IDf being significantly higher than that of other peptides, even higher than mix (IDh). Moreover, IDf displayed a significant detection advantage when compared with the other 3 peptides located in the RBD region. These results indicated that IDf was a dominant B-cell epitope, which was of great significance for the development of SARS-CoV-2 detection kits and may have reference value for the development of peptide vaccines.

Amrun et al. [11] found that both the sensitivity and specificity of S14P5 (TESNKKFLPFQQFGRDIA) for the detection of serum samples from 79 COVID-19 patients were above 86%, higher than that of the 9 peptides in this study. These results further indicated that the function of each B-cell epitope is diverse, and it is valuable to screen for dominant epitope. In this study, mix (IDh) was a mixture of 6 peptides that contained the S14P5 amino acid sequence; however, its positive reaction rate of 83% may due to the following reasons: (1) the amino acid sequence of S14P5 was distributed on 2 different peptides in mix (IDh) (shown in online suppl. Table 1; see www.karger.com/doi/10.1159/000517717 for all online suppl. material), affecting its binding ability (2) or the different sample size and the composition ratio of patients with different disease severity may have caused the difference. Among 165 patients in this study, 19.4% (32) were asymptomatic; asymptomatic patients usually had lower antibody titers.

Antibodies were the main evaluation indicator of vaccine efficacy, while neutralizing antibody titers could effectively reflect the blocking of antibodies against viruses. This study found that the positive rates of IgG and total antibody in 165 convalescent COVID-19 patients were both 98.8%, consistent with previous reports [12–14]. The positive reaction rate of the neutralizing antibody in the 150 tested patients was 90.67%, and the median (IQR) was 1:32 (1:24). However, the S/CO values of the 8 peptides were not correlated with the neutralizing antibody titers. Notably, IDd, IDE, IDf, and IDg were located in RBD, and none of these 4 epitopes was correlated with neutralizing antibody. The result indicated that not all the B-cell epitopes located in the RBD was associated with neutralization capacity. However, this study showed that the RBD and mix (IDh) were significantly correlated with the neutralizing antibody titers, suggesting that the ability of novel coronavirus antibody for virus neutralization may require multiple epitope sites; however, the existence of predominant epitopes cannot be ruled out.

This study conducted comprehensive antibody detection and analysis of serum samples from 165 convalescent COVID-19 patients, but the number of epitopes we analyzed were limited. With the continuous discovery of new B-cell epitopes of SARS-CoV-2, the peptide combinations for serological detection are constantly improving [15–17]. This study found a high overall positive reaction rate and a high detection rate for IDf in asymptomatic patients. The combination of the IDf with other peptides...
showed obvious detection advantages in improving the positive rate of serological detection, which is of great significance for the detection of antibodies against COVID-19.

Statement of Ethics

This research comply with the guidelines for human studies, and the research was reviewed by the Ethics Committee of Shenzhen Center for Disease Control and Prevention in Guangdong Province (QS20200700048), which agreed that the subjects were exempt from signing the informed consent. The supporting materials were attached.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

1 Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020;395(10223):470–3.
2 Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020; 395(10223):514–23.
3 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 2020;181(2):281–92.e6.
4 Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*. 2020;5(4):562–9.
5 Hoffmann M, Kleine-Weber H, Schroder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271–80.e8.
6 Zhang BZ, Hu YF, Chen LL, Yau T, Tong YG, Hu JC, et al. Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients. *Cell Res*. 2020;30(8):702–4.
7 Wei P-F. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). *Chin Med J*. 2020;133(9):1087–95.
8 Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, et al. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. *Emerg Microbes Infect*. 2020;9(1):1988–96.
9 Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. *Emerg Microbes Infect*. 2020;9(1):275–7.
10 Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, et al. Molecular architecture of the SARS-CoV-2 virus. *Cell*. 2020;183(3):370–38.e13.
11 Amrun SN, Lee CY, Chee RS, Amrun SN, Lee CY, Chee RS, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralizing antibodies in COVID-19 patients. *Nat Commun*. 2020;11(1):2806.